MedTrace Logo

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

NCT05495620 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-08-10

No results posted yet for this study

Summary

Research question: Is KRd therapy effective and safe in the real-world Asian patients?

Primay objective: To evaluate the effectiveness of KRd in RRMM patients

Secondary objectives:

To evaluate the effectiveness of investigational treatment strategy by

* PFS difference according to the high-risk disease subgroups and previous treatment
* OS
* Overall response rate and clinical benefit rate
* Duration of response To evaluate the safety and tolerability of KRd in RRMM patients

Conditions

  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory

Interventions

DRUG

Carfilzomib

Intravenous carfilzomib, lenalidomide, dexamethasone

DRUG

Lenalidomide

Oral

DRUG

Dexamethasone

Oral or intravenous

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Dong-A University Hospital

    lead OTHER

Principal Investigators

  • Sung-Hyun Kim, MD, Ph.D · Dong-A University Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-01-31
Completion
2023-09-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05495620 on ClinicalTrials.gov